HC Wainwright Issues Positive Forecast for LifeMD Earnings

LifeMD, Inc. (NASDAQ:LFMD) – Research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of LifeMD in a note issued to investors on Wednesday, March 11th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.04) per share for the quarter, up from their previous estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD’s Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.33 EPS.

Several other equities research analysts have also commented on the stock. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of LifeMD in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of LifeMD in a research note on Monday, December 29th. Wall Street Zen lowered shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Mizuho lowered their target price on LifeMD from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, November 19th. Finally, Loop Capital set a $10.00 target price on LifeMD in a research report on Thursday. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

LifeMD Price Performance

NASDAQ:LFMD opened at $3.98 on Friday. LifeMD has a 1-year low of $2.56 and a 1-year high of $15.84. The company has a 50-day moving average of $3.33 and a 200 day moving average of $4.54. The firm has a market cap of $190.92 million, a PE ratio of 15.31 and a beta of 1.92.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.03). The firm had revenue of $46.87 million for the quarter, compared to analysts’ expectations of $48.57 million. LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in shares of LifeMD during the 4th quarter worth approximately $36,000. Magnus Financial Group LLC purchased a new position in LifeMD in the fourth quarter worth $41,000. Jain Global LLC acquired a new position in shares of LifeMD during the fourth quarter worth $45,000. Quarry LP purchased a new stake in shares of LifeMD during the 3rd quarter valued at $52,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares in the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.